MX2011008749A - Variantes de union a anti-albumina de suero mejoradas. - Google Patents

Variantes de union a anti-albumina de suero mejoradas.

Info

Publication number
MX2011008749A
MX2011008749A MX2011008749A MX2011008749A MX2011008749A MX 2011008749 A MX2011008749 A MX 2011008749A MX 2011008749 A MX2011008749 A MX 2011008749A MX 2011008749 A MX2011008749 A MX 2011008749A MX 2011008749 A MX2011008749 A MX 2011008749A
Authority
MX
Mexico
Prior art keywords
serum albumin
albumin binding
improved anti
binding variants
variants
Prior art date
Application number
MX2011008749A
Other languages
English (en)
Inventor
Carolyn Enever
Angelis Elena De
Haiqun Liu
Oliver Schon
Christopher Plummer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2011008749A publication Critical patent/MX2011008749A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a variantes mejoradas del dominio variable sencillo de inmunoglobulina anti-albúmina de suero DOM7h-11, así como a ligandos y conjugados de fármacos que comprenden dichas variantes, composiciones, ácido nucleicos, vectores y huéspedes.
MX2011008749A 2009-02-19 2010-02-17 Variantes de union a anti-albumina de suero mejoradas. MX2011008749A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30
PCT/EP2010/052008 WO2010094723A2 (en) 2009-02-19 2010-02-17 Improved anti-serum albumin binding variants

Publications (1)

Publication Number Publication Date
MX2011008749A true MX2011008749A (es) 2011-09-06

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008749A MX2011008749A (es) 2009-02-19 2010-02-17 Variantes de union a anti-albumina de suero mejoradas.

Country Status (25)

Country Link
US (3) US9534043B2 (es)
EP (3) EP2398826B1 (es)
JP (2) JP5759391B2 (es)
KR (1) KR101819754B1 (es)
CN (1) CN102405233B (es)
AR (1) AR075505A1 (es)
AU (1) AU2010215482B2 (es)
BR (1) BRPI1013341B1 (es)
CA (2) CA3079184A1 (es)
CL (1) CL2011002025A1 (es)
CO (1) CO6410311A2 (es)
DO (1) DOP2011000266A (es)
EA (1) EA028178B1 (es)
ES (2) ES2655071T3 (es)
HK (1) HK1247944A1 (es)
IL (1) IL214480A0 (es)
MA (1) MA33051B1 (es)
MX (1) MX2011008749A (es)
NZ (1) NZ595242A (es)
PE (1) PE20120001A1 (es)
SG (1) SG173489A1 (es)
TW (1) TW201042039A (es)
UY (1) UY32450A (es)
WO (1) WO2010094723A2 (es)
ZA (1) ZA201105657B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110137819A (ko) * 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
CA2777312A1 (en) * 2009-10-27 2011-05-05 Inusha De Silva Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
JP2013538566A (ja) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
BR112013013003A2 (pt) * 2010-11-24 2016-08-09 Glaxo Group Ltd proteína de ligação de antígeno, e, composição farmacêutica
EP2646467A2 (en) 2010-12-01 2013-10-09 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
EP2670778A1 (en) 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
SG11201810256XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding relaxin
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
MA49249A (fr) 2017-06-05 2021-04-14 Numab Therapeutics AG Nouveaux anticorps anti-hsa

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
EP2172553A1 (en) 2004-03-24 2010-04-07 Domantis Limited Gas1 universal leader
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007066109A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20110236380A1 (en) 2008-11-26 2011-09-29 De Wildt Rudolf M T Ligands that bind il-13
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
KR101820968B1 (ko) 2009-02-19 2018-01-23 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
CA2768460A1 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
WO2011131659A2 (en) * 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains

Also Published As

Publication number Publication date
NZ595242A (en) 2013-11-29
WO2010094723A3 (en) 2011-04-21
DOP2011000266A (es) 2011-12-31
AR075505A1 (es) 2011-04-06
KR20110127223A (ko) 2011-11-24
WO2010094723A2 (en) 2010-08-26
JP6100315B2 (ja) 2017-03-22
CO6410311A2 (es) 2012-03-30
US20170298121A1 (en) 2017-10-19
JP5759391B2 (ja) 2015-08-05
BRPI1013341B1 (pt) 2021-09-08
EP3330287A1 (en) 2018-06-06
EP3330287B1 (en) 2019-12-18
JP2012517820A (ja) 2012-08-09
US20200283512A1 (en) 2020-09-10
MA33051B1 (fr) 2012-02-01
ZA201105657B (en) 2012-04-25
CN102405233B (zh) 2014-11-26
HK1247944A1 (zh) 2018-10-05
US10696738B2 (en) 2020-06-30
JP2015204831A (ja) 2015-11-19
EA028178B1 (ru) 2017-10-31
EP3656788A3 (en) 2020-07-29
CL2011002025A1 (es) 2012-04-09
UY32450A (es) 2010-09-30
CA2767752A1 (en) 2010-08-26
IL214480A0 (en) 2011-09-27
CN102405233A (zh) 2012-04-04
BRPI1013341A2 (pt) 2016-10-11
CA2767752C (en) 2020-07-07
CA3079184A1 (en) 2010-08-26
KR101819754B1 (ko) 2018-01-18
EP3656788A2 (en) 2020-05-27
PE20120001A1 (es) 2012-02-12
AU2010215482A1 (en) 2011-08-25
ES2655071T3 (es) 2018-02-16
SG173489A1 (en) 2011-09-29
AU2010215482B2 (en) 2014-02-13
EP2398826B1 (en) 2017-10-25
TW201042039A (en) 2010-12-01
EA201171068A1 (ru) 2012-02-28
ES2774192T3 (es) 2020-07-17
US9534043B2 (en) 2017-01-03
US20110305696A1 (en) 2011-12-15
EP2398826A2 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012000765A (es) Dominios variables sencillos de union de albumina anti-suero mejorados.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
AU2015370918A8 (en) Binding protein drug conjugates comprising anthracycline derivatives
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX2012003939A (es) Fusiones y conjugados de farmaco.
WO2011086143A3 (en) Liver targeting domain antibodies
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
CA2817002A1 (en) Base modified oligonucleotides
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
WO2011112566A3 (en) Basigin binding proteins
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.
NZ626296A (en) Compositions and methods for antibodies targeting factor p

Legal Events

Date Code Title Description
FA Abandonment or withdrawal